# The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

> **NCT03463057** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 109 (actual)

## Conditions studied

- NHL
- DLBCL

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03463057
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-30
- **Primary completion:** 2024-01-18
- **Final completion:** 2027-01
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03463057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03463057, "The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03463057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*